中医药调控HIF-1α通路治疗呼吸系统疾病的研究进展
Research Progress in Traditional Chinese Medicine Targeting the HIF-1α Pathway for Respiratory Diseases Therapy
DOI: 10.12677/acm.2025.15113150, PDF,   
作者: 崔彤彤：黑龙江中医药大学研究生院，黑龙江 哈尔滨；王雪慧*：黑龙江中医药大学附属第一医院呼吸科，黑龙江 哈尔滨
关键词: HIF-1α；呼吸系统；中医药；研究进展；综述；HIF-1α； Respiratory System； Traditional Chinese Medicine (TCM)； Research Progress； Review
摘要: 缺氧诱导因子-1α (HIF-1α)在呼吸系统疾病发病过程中可以通过调节氧化应激、炎症反应、血管生成、细胞凋亡和自噬等途径促进细胞的存活和恢复，呼吸系统的疾病关系密切，HIF-1α的下调在缺氧下显著增加了细胞毒性和DNA损伤，对支气管上皮细胞造成一定损伤。既往诸多研究表明中医药干预HIF-1α信号通路治疗呼吸系统疾病。本文章总结了HIF-1α信号通路与呼吸系统疾病发病机制之间的联系，并概述了中医药在调节HIF-1α信号通路以治疗呼吸系统疾病的研究进展，以期为中医药防治提供新思路。
Abstract: Hypoxia-inducible factor-1α (HIF-1α) plays a critical role in the pathogenesis of respiratory diseases by regulating processes such as oxidative stress, inflammatory responses, angiogenesis, apoptosis, and autophagy, thereby promoting cell survival and recovery. The downregulation of HIF-1α under hypoxic conditions significantly increases cytotoxicity and DNA damage, causing certain harm to bronchial epithelial cells. Numerous previous studies have demonstrated that Traditional Chinese Medicine (TCM) can intervene in the HIF-1α signaling pathway for the treatment of respiratory diseases. This article summarizes the relationship between the HIF-1α signaling pathway and the pathogenesis of respiratory diseases, and reviews recent advances in TCM targeting the regulation of the HIF-1α signaling pathway for the treatment of respiratory disorders, aiming to provide new insights for the prevention and treatment of these diseases with TCM.
文章引用：崔彤彤, 王雪慧. 中医药调控HIF-1α通路治疗呼吸系统疾病的研究进展[J]. 临床医学进展, 2025, 15(11): 712-718. https://doi.org/10.12677/acm.2025.15113150

参考文献

[1] Morris, D.R., Qu, Y., Haas de Mello, A., Jones-Hall, Y.L., Liu, T., Weglarz, M., et al. (2025) Role of Hypoxia-Inducible Factors in Respiratory Syncytial Virus Infection-Associated Lung Disease. International Journal of Molecular Sciences, 26, Article 3182. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, S., Yang, D., Yuan, C., Wu, Y., Wang, Q., Wu, Y., et al. (2025) Herbal Formula Yi‐Fei‐Jie‐Du‐Tang Regulates Epithelial‐Mesenchymal Transition and Vasculogenic Mimicry in Lung Cancer via HIF1α‐Mediated Ferroptosis. Advanced Biology, 9, e2400306. [Google Scholar] [CrossRef] [PubMed]
[3] Hua, J., Liu, L., He, B., Hu, W., Wu, Y., Han, Y., et al. (2025) Hif-1α Protects Cigarette-Induced Airway Epithelial Cell Apoptosis in COPD by Activating Redd1. International Immunopharmacology, 161, Article 115062. [Google Scholar] [CrossRef] [PubMed]
[4] Ashraf, A., Zechmann, B. and Bruce, E.D. (2025) Hypoxia-Inducible Factor 1α Modulates Acrolein-Induced Cellular Damage in Bronchial Epithelial Cells. Toxicology, 515, Article 154158. [Google Scholar] [CrossRef] [PubMed]
[5] Shukla, S.D., Walters, E.H., Simpson, J.L., Keely, S., Wark, P.A.B., O’Toole, R.F., et al. (2020) Hypoxia‐Inducible Factor and Bacterial Infections in Chronic Obstructive Pulmonary Disease. Respirology, 25, 53-63. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, R., Zhong, Y., Liu, Q., Zhang, M., Wang, D., Li, S., et al. (2025) CGRP Alleviates Lipopolysaccharide-Induced ARDS Inflammation via the HIF-1α Signaling Pathway. Clinical Science, 139, 373-387. [Google Scholar] [CrossRef] [PubMed]
[7] Yin, L., Li, S. and Pan, L. (2025) A Study on the Influencing Factors of Early Clinical Stability in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Complicated by Pneumonia. Journal of Thoracic Disease, 17, 6837-6849. [Google Scholar] [CrossRef] 
[8] Zhou, W., Qu, J., Xie, S., Sun, Y. and Yao, H. (2021) Mitochondrial Dysfunction in Chronic Respiratory Diseases: Implications for the Pathogenesis and Potential Therapeutics. Oxidative Medicine and Cellular Longevity, 2021, Article ID: 5188306. [Google Scholar] [CrossRef] [PubMed]
[9] Atalay, N.A., Yormaz, B., Şahin, A., Sonmez, G., Colkesen, S.S., Vatansev, H., et al. (2025) Elevated HIF-1α as a Diagnostic Biomarker in COPD: Correlations with EPO, Emphysema Index, and Pulmonary Function. Respiratory Medicine, 245, Article 108184. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, K., Zhou, F., Zhu, C., Yuan, L., Li, D., Wang, J., et al. (2025) Role of Digoxin in Preventing Cigarette Smoke-Induced COPD via HIF-1α Inhibition in a Mouse Model. International Journal of Chronic Obstructive Pulmonary Disease, 20, 1665-1678. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, X., Zhou, Y. and Zhang, H. (2025) Clinical Significance of HIF-1α, ET-1, and NO as Biomarkers in Chronic Obstructive Pulmonary Disease Patients with Pulmonary Hypertension. Biomolecules and Biomedicine, 25, 1389-1395. [Google Scholar] [CrossRef] [PubMed]
[12] Zhou, L., Zhang, H., Liu, L., Zhang, F., Wang, L., Zheng, P., et al. (2025) Intermittent Hypoxia Aggravates Asthma Inflammation via NLRP3/IL-1β-Dependent Pyroptosis Mediated by HIF-1α Signalling Pathway. Chinese Medical Journal, 138, 1714-1729. [Google Scholar] [CrossRef] [PubMed]
[13] Wan, M., Yu, Q., Xu, F., You, L.X., Liang, X., kang Ren, K., et al. (2024) Novel Hypoxia-Induced HIF-1α Activation in Asthma Pathogenesis. Respiratory Research, 25, Article No. 287. [Google Scholar] [CrossRef] [PubMed]
[14] Nguyen, V., Zhang, Q., Pan, F., Jin, Q., Sun, M., Tangthianchaichana, J., et al. (2023) Zi-Su-Zi Decoction Improves Airway Hyperresponsiveness in Cough-Variant Asthma Rat Model through PI3K/Akt1/mTOR, JAK2/STAT3 and HIF-1α/NF-κB Signaling Pathways. Journal of Ethnopharmacology, 314, Article 116637. [Google Scholar] [CrossRef] [PubMed]
[15] Salama, A., El-Fadaly, A.A. and Elgohary, R. (2024) Effect of Atorvastatin on Lipopolysaccharide-Induced Lung Inflammation and Hypoxia in Mice; Modulation of HIF-1α, CINC and MIP-2. Immunopharmacology and Immunotoxicology, 47, 85-93. [Google Scholar] [CrossRef] [PubMed]
[16] 王晓格, 杨林, 冯姝华. 血清UCP2、HIF-1α水平对新生儿肺炎病情、疾病转归的预测效能[J]. 临床医学, 2024, 44(12): 4-7.
[17] Wang, M., Guo, Y., Liu, Y., Ma, S., Zhang, J., Li, Y., et al. (2025) UBXD8 Promotes Lung Cancer Progression and Activates the HIF-1α Pathway. Biochemical Pharmacology, 240, Article 117078. [Google Scholar] [CrossRef] [PubMed]
[18] Li, Y., Yang, G., Li, Q., Zhang, Y., Zhang, S., Zhou, T., et al. (2025) Guiqi Baizhu Decoction Enhances Radiosensitivity in Non-Small Cell Lung Cancer by Inhibiting the HIF-1α/DNA-PKCS Axis-Mediated DNA Repair. Phytomedicine, 140, Article 156591. [Google Scholar] [CrossRef] [PubMed]
[19] Liang, J., Ran, Y., Hu, C., Zhou, J., Ye, L., Su, W., et al. (2025) Inhibition of HIF-1α Ameliorates Pulmonary Fibrosis by Suppressing M2 Macrophage Polarization through PRMT1/STAT6 Signals. International Immunopharmacology, 146, Article 113931. [Google Scholar] [CrossRef] [PubMed]
[20] Chen, H., Zhang, Z., Song, Y., Hu, Q., Jin, D., Liu, S., et al. (2025) Unraveling the Therapeutic Mechanisms of Bufei Yiqi Decoction in Pulmonary Fibrosis: Modulation of Autophagy and Glycolysis Pathways. International Immunopharmacology, 162, Article 115030. [Google Scholar] [CrossRef] [PubMed]
[21] Luan, X., Zhu, D., Hao, Y., Xie, J., Wang, X., Li, Y., et al. (2025) Qibai Pingfei Capsule Ameliorated Inflammation in Chronic Obstructive Pulmonary Disease (COPD) via HIF-1 Α/Glycolysis Pathway Mediated of Bmal1. International Immunopharmacology, 144, Article 113636. [Google Scholar] [CrossRef] [PubMed]
[22] Yang, Q., Yin, D., Wang, H., et al. (2024) Uncovering the Action Mechanism of Shenqi Tiaoshen Formula in the Treatment of Chronic Obstructive Pulmonary Disease through Network Pharmacology, Molecular Docking, and Experimental Verification. Journal of Traditional Chinese Medicine, 44, 770-783.
[23] 罗斌, 陈雨燕, 邱秀芳, 等. 清金化痰汤抑制IL-6/STAT3/HIF-1α通路介导的细胞凋亡和炎症治疗慢性阻塞性肺疾病机制研究[J]. 陕西中医, 2025, 46(4): 462-466.
[24] 范晓璇, 张庆祥, 颜培正, 等. 基于mTOR/HIF-1α通路探讨温阳化饮方对哮喘寒饮蕴肺证大鼠气道炎症细胞自噬的机制研究[J]. 时珍国医国药, 2024, 35(8): 1886-1890.
[25] Fang, Y., Qiu, J., Xu, Y., Wu, Q., Huo, X. and Liu, S. (2025) Ophiopogonin D Alleviates Sepsis-Induced Acute Lung Injury through Improving Microvascular Endothelial Barrier Dysfunction via Inhibition of HIF-1α-VEGF Pathway. Cell Biochemistry and Biophysics, 83, 2519-2531. [Google Scholar] [CrossRef] [PubMed]
[26] Pan, T., Wu, J., Qiu, X., Zhu, D., Wang, J., Li, T., et al. (2024) Identification of Potential Mechanisms of Schisandrin B in the Treatment of Idiopathic Pulmonary Fibrosis by Integrating Network Pharmacology and Experimental Validation. Naunyn-Schmiedeberg’s Archives of Pharmacology, 398, 5389-5403. [Google Scholar] [CrossRef] [PubMed]
[27] Hu, Y., Fan, Q., Qiao, B., Xu, O., Lv, B., Han, N., et al. (2024) Alleviatory Role of panax Notoginseng Saponins in Modulating Inflammation and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease: Mechanisms and Implications. COPD: Journal of Chronic Obstructive Pulmonary Disease, 21, Article 2329282. [Google Scholar] [CrossRef] [PubMed]
[28] Ding, C., Guo, Z., Liao, Q., Zuo, R., He, J., Ye, Z., et al. (2024) Network Pharmacology and Machine Learning Reveal Salidroside’s Mechanisms in Idiopathic Pulmonary Fibrosis Treatment. Journal of Inflammation Research, 17, 9453-9467. [Google Scholar] [CrossRef] [PubMed]

为你推荐